Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Sunday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price target for the company.

Lipocine Stock Up 1.0 %

Lipocine stock opened at $5.15 on Friday. Lipocine has a 52-week low of $2.40 and a 52-week high of $11.79. The firm has a market capitalization of $27.55 million, a price-to-earnings ratio of -6.78 and a beta of 1.24. The firm has a 50-day moving average price of $5.11 and a two-hundred day moving average price of $5.56.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. Research analysts expect that Lipocine will post -0.78 earnings per share for the current year.

Institutional Trading of Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine at the end of the most recent reporting period. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.